Tuesday, July 21, 2020 2:25:54 PM
WeeZuhl, i always appreciate your insights. What i was referring to about the FDA was that they told Nas that the amount of time until the drug kicks in (i forget the official name for this) on the original version of SequestOx was a labelling matter—ie that it could be taken care of adequately by simply stating on the label of the bottle to take the pill either one hour before eating or two hours after eating a fatty meal—SAME AS MANY OTHER DRUGS—but then when we were ready to roll, they changed their requirement, would not allow simple labeling and crashed our opportunity to launch the product, sending us back to the drawing board for another few years and millions of dollars.
That is nonsense. First of all, I don't believe that bullcrap story and never have. Exquisite notes are taken during those FDA meetings ON BOTH SIDES, and those notes are exchanged so there is no confusion. If that were true, Nasrat would be able to easily release the notes of the meeting and prove his case, which he never has. I am not aware of these MANY OTHER DRUGS in which a lack of bioequivalence is handled with a labeling change. Can someone name a few? Name one? He failed to recognize an NDA app would not be treated with the same kid gloves as an ANDA app. The reason he didn't was because his head was up Camargo's butt while their hands were in both our pockets. I bet it was CAMARGO who spun him the tale about a labeling change, and NOT the FDA.
The brilliance of the SequestOx idea is that it would be a quick and easy way to get the 2 bead system on the market. It never was going to be a blockbuster, but it would have been a great flagship. When it ceased being quick and easy, it ceased being smart, but years later and after millions more, we were still blowing through shares pursuing it. Doubling and then tripling down on a bad bet. And we have literally NOTHING to show for it, except maybe Nasrat got a patent out of it, again at our expense. Meanwhile, through his own incompetence and stink of failure, Nasrat lets the share count go too high and share price fall too low, so that he gets his dilution machine taken away. When he finally does make a positive pivot to the CNS stimulants, he has to fund the R&D with sketchy Chinese government money. The only two worthy assets Nasrat has ever brought to Elite are Adderall and Adderall XR, and who owns them now? Mother-lovin' MIKAH. No kidding. Elite doesn't have a pot to piss in, other than 450M newly-authorized shares and a shiny, new dilution machine, but freakin' MIKAH owns the Adderalls. Didn't we already merge with that company in 2013?
Don't worry, all, Nasrat says he really hopes Elite is able to acquire the Adderall ANDAS some day. More on that to come....
Occam's razor: the simplest solution is most likely the right one.
Hanlon's razor: never attribute to malice that which is adequately explained by stupidity.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
